PDE4
Assets acting on this target.
- Class
- Phosphodiesterase-4 inhibitor
Phosphodiesterase-4 (PDE4) is an enzyme that breaks down cyclic adenosine monophosphate (cAMP), a small signaling molecule inside cells that dampens inflammatory activity when its levels are high. PDE4 is expressed abundantly in immune cells such as monocytes, macrophages, and T cells, as well as in epithelial and skin cells, where it keeps cAMP levels in check. Inhibiting PDE4 prevents the breakdown of cAMP, allowing it to accumulate and reduce the production of pro-inflammatory mediators such as tumor necrosis factor and various interleukins. This rationale makes PDE4 inhibition broadly relevant to chronic inflammatory diseases, including inflammatory skin conditions like psoriasis and atopic dermatitis, inflammatory bowel conditions, and airway diseases such as chronic obstructive pulmonary disease, where excessive inflammatory signaling drives tissue damage and symptoms. Because PDE4 is expressed in many organ systems, inhibitors can be formulated for systemic use, applied topically to the skin, or engineered as prodrugs that release the active drug locally, such as within the colon, to concentrate the anti-inflammatory effect where disease is active while limiting exposure elsewhere in the body. This flexibility in delivery reflects an effort to preserve efficacy while managing the tolerability challenges associated with broader PDE4 inhibition.
Related mechanisms
PDE4 drugs compared
11 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| apremilastOtezla | Amgen | small molecule | Approved | Approved in Psoriasis; Approved in Psoriatic Arthritis |
| crisaboroleEucrisa | Pfizer | small molecule | Approved | Approved in Atopic Dermatitis |
| difamilastMoizerto / Adquey | Acrotech Biopharma, Otsuka Holdings | small molecule | Approved | Approved in Atopic Dermatitis |
| Roflumilast (Daliresp)Daliresp | AstraZeneca | small molecule | Approved | Approved in Chronic Obstructive Pulmonary Disease |
| Roflumilast (Zoryve foam)Zoryve foam | Arcutis Biotherapeutics, Sato Pharmaceutical Co., Ltd. | small molecule | Approved | Approved in Psoriasis; Approved in Seborrheic Dermatitis |
| Roflumilast (Zoryve)Zoryve | Arcutis Biotherapeutics, Huadong Medicine, Sato Pharmaceutical Co., Ltd. | small molecule | Approved | Approved in Atopic Dermatitis; Approved in Psoriasis |
| Mufemilast | Tianjin Hemay Pharmaceutical | small molecule | Phase 3 | Phase 3 in Psoriasis; Phase 3 in Ulcerative Colitis |
| Prifemilast (HPP737) | cAMPfield Therapeutics, Newsoara Biopharma, vTv Therapeutics | small molecule | Phase 3 | Phase 3 in Psoriasis |
| ALTO-101 | Alto Neuroscience | small molecule | Phase 2 | Not recorded |
| Morcamilast | Meiji Seika Pharma | small molecule | Phase 2 | Phase 2 in Psoriasis |
| PALI-2108 | Palisade Bio | Small molecule (colon-targeted PDE4 inhibitor prodrug) | Phase 2 | Phase 2 in Ulcerative Colitis; Phase 1 in Crohn's Disease |